Pulmotect’s lead product, PUL-042, is a clinical stage inhaled therapeutic that stimulates the innate immune system in the lung to provide immediate and effective protection against all major classes of pathogens. Effectiveness against viral, bacterial and fungal infection have been demonstrated in animal studies including immunosuppressed animal models.

Despite a surface area nearly the size of a tennis court, the lungs are capable of defending against inhaled pathogens however this defense can be overwhelmed particularly in populations such as the immunocompromised (cancer, transplant, elderly, etc.) or in any population exposed to pathogens (pandemic or epidemic). PUL-042 has the potential to prevent and treat respiratory infections by powerfully boosting the bodies natural innate immune defense within the lungs.

  • Synergistic combination that activates the innate surface immunity of lung epithelial cells1       :
    • Pam2CSK4 – TLR 2/6 agonist
    • ODNM362 – TLR 9 agonist
  • Rapid host response within minutes
    • Broad spectrum, locally acting pathogen-agnostic killing; primarily ROS-mediated 2
    • Single dose provides up to 7 days of sustained protection in animal studies
    • Activates adaptive immune system 3